News for Healthier Living

Dana-Farber Research Supports FDA Approval of New Therapy for "Double-Positive" Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with "double-positive" metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute. The PATINA trial demonstrated that the addition of the CDK 4/6 inhibitor palbociclib to standard therapy in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer resulted in a more than 15-month improvement in progression-free survival. The findings were reported in the New England Journal of Medicine and also presented at the San Antonio Breast Cancer Symposium in December 2024.

July 6, 2026


July 7 2026

July 6 2026

July 3 2026

July 2 2026

July 1 2026

June 30 2026

June 29 2026

June 26 2026

June 25 2026

June 24 2026

June 23 2026